Skip to main content

Tekturna News

Noden Pharma Announces FDA Approval of Tekturna (aliskiren) Oral Pellets for the Treatment of Hypertension in Adults and Children 6 Years of Age and Older

DUBLIN, Nov. 15, 2017 /PRNewswire/ – Noden Pharma DAC, a global specialty pharmaceutical company that is focused on acquiring prescription medicines across a broad range of therapeutic areas,...

FDA Medwatch Alert: Aliskiren-containing Medications: Drug Safety Comunication - New Warning and Contraindication

including: Amturnide (aliskiren hemifumarate, amlodipine besylate, and hydrochlorothiazide) Tekturna (aliskiren hemifumarate) Tekturna HCT (aliskiren hemifumarate and hydrochlorothiazide) Tekamlo...

Novartis Gains FDA Approval for Amturnide, a Triple-Combination Pill to Treat High Blood Pressure in Patients Uncontrolled on Two Medications

EAST HANOVER, N.J., December 22, 2010, 2010 /PRNewswire/ – Today Novartis announced that the US Food and Drug Administration (FDA) approved Amturnide (aliskiren, amlodipine and hydrochlorothiazide)...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

High Blood Pressure, Hypertension

Tekturna patient information at Drugs.com